Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
Lotte Simonsen, Jesper Lau, Thomas Kruse, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0264974-e0264974
Open Access | Times Cited: 24

Showing 24 citing articles:

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, et al.
Molecular Metabolism (2022) Vol. 63, pp. 101533-101533
Open Access | Times Cited: 86
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
Tina Zimmermann, Leo Thomas, Tamara Baader-Pagler, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101633-101633
Open Access | Times Cited: 79
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 57
Targeting the incretin system in obesity and type 2 diabetes mellitus
Saleem Ansari, Bernard Khoo, Tricia Tan
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 8, pp. 447-459
Closed Access | Times Cited: 30
Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, et al.
Molecular Metabolism (2023) Vol. 78, pp. 101801-101801
Open Access | Times Cited: 24
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 9
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
Jonathan Brix Winther, Jens J. Holst
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 6
The dual GCGR/GLP‐1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
Leo Thomas, Eric Martel, Wolfgang Rist, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2368-2378
Open Access | Times Cited: 5
Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy
David C. D. Hope, Tricia Tan
Peptides (2023) Vol. 162, pp. 170962-170962
Closed Access | Times Cited: 11
Rational design of dual-agonist peptides targeting GLP-1 and NPY2 receptors for regulating glucose homeostasis and body weight with minimal nausea and emesis
Jing Liu, Weiwen Lu, Han Wu, et al.
European Journal of Medicinal Chemistry (2025), pp. 117320-117320
Closed Access
Oxyntomodulin-past, present and future
Jens J. Holst, Mette M. Rosenkilde
Peptides (2025), pp. 171393-171393
Closed Access
Adaptive infusion of a glucagon‐like peptide‐1/glucagon receptor co‐agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial
David C. D. Hope, Saleem Ansari, Sirazum Choudhury, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1479-1491
Open Access | Times Cited: 3
Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues
Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 13
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
Emma Rose McGlone, Tricia Tan
Peptides (2024) Vol. 176, pp. 171219-171219
Open Access | Times Cited: 2
Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients
Thomas Monfeuga, Jenny Norlin, Anne Bugge, et al.
Molecular Metabolism (2023) Vol. 79, pp. 101850-101850
Open Access | Times Cited: 6
In Vitro CYP450 Enzyme Downregulation by GLP-1/Glucagon Coagonist Does Not Translate to Observed Drug-Drug Interactions in the Clinic
Carolina Säll, Lene Alifrangis, Kirsten Dahl, et al.
Drug Metabolism and Disposition (2022) Vol. 50, Iss. 8, pp. 1087-1097
Open Access | Times Cited: 10
Co-agonist therapeutics come of age for obesity
Tricia Tan
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 2, pp. 66-67
Closed Access | Times Cited: 9
Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin
Richard J. MacIsaac, Gary Deed, Michael C dʼEmden, et al.
Diabetes Therapy (2023) Vol. 14, Iss. 12, pp. 1997-2014
Open Access | Times Cited: 5
The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies
Peng Jiang, Ying Zeng, Wen Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116485-116485
Open Access | Times Cited: 1
Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy
Xiao Sun, Dawei Yang, Y. Li, et al.
Peptides (2024) Vol. 177, pp. 171203-171203
Closed Access | Times Cited: 1
Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists
Xiaolong Zhang, Y. Cai, Zhihong Yao, et al.
Peptides (2023) Vol. 161, pp. 170948-170948
Closed Access | Times Cited: 3
Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity
Jing Xu, Shuang Wang, Han Wu, et al.
Peptides (2023) Vol. 169, pp. 171073-171073
Closed Access | Times Cited: 3
Physiology and pharmacology of glucagon-like peptide-1 receptor
Д. В. Куркин, Д. А. Бакулин, Е. И. Морковин, et al.
Pharmacy & Pharmacology (2024) Vol. 11, Iss. 4, pp. 347-380
Open Access
Multi‐target Peptides for the Treatment of Metabolic Diseases
Martin Bossart, Gerhard Heßler
(2024), pp. 269-288
Closed Access
Page 1

Scroll to top